TYRATyra Biosciences, Inc.

Healthcare
$19.91+59% 1Y

Price

+59%1Y

End-of-day closes, not the intraday tick.

RyuScore

Weak, higher than 5% of companies
7/100
Seven criteria, weighted: see how it is built

The five questions

2 of 5 available

Only two of the five can be answered for TYRA today. The rest need figures this filer has not published. The tabs above still show whatever data does exist.

  • Is the business good?not enough filed
  • Is it safe?Mixed
  • Is the price fair?not enough filed
  • Is it growing?not enough filed
  • What is the market doing?Mixed
What they do

We are a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. Our in-house precision medicine platform, SNÅP, enables rapid and precise drug design through iterative molecular SNÅPshots that help us design and predict which product candidates may demonstrate the highest potency, selectivity and tolerability in the clinic.

In the company’s own words · 10-K filed Mar 2, 2026 · SEC EDGAR

P/En/a
Market value$1.84B
1 year+59%
5 yearsn/a

Charts

As reported to the SEC, without any scoring.

The next results filing is expected around Nov 4, 2026, the same week as a year ago.

What the company said

The company's own words from its current reports to the SEC, newest first

  1. Sep 15, 2026On September 14, 2026, Tyra Biosciences, Inc. (TYRA or the Company) entered into an underwriting agreement (the Underwriting Agreement) with Jefferies LLC, Guggenheim Securities, LLC, Cantor Fitzgerald & Co. and Barclays Capital Inc., as representatives of the several underwriters named therein (collectively, the …Other event · Form 8-K
  2. Sep 9, 2026On September 9, 2026, Tyra Biosciences, Inc. (TYRA or the Company) announced initial results from SURF302, its Phase 2 study evaluating oral dabogratinib in patients with Fibroblast Growth Factor Receptor (FGFR) 3-altered low-grade intermediate-risk non-muscle invasive bladder cancer (LG IR NMIBC)Other event · Form 8-K
  3. Aug 4, 2026Tyra Biosciences Reports Second Quarter 2026 Financial Results and Recent Highlights.Earnings release · press release

Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.

On our screens:Most shorted stocks

Biotechnology

Ranks #154 of 196 by RyuScore

Compare peers
GLUE-0.05%
Monte Rosa Therapeutics, Inc.
RAPP+2.9%
Rapport Therapeutics, Inc.
MESO+3.9%
Mesoblast Limited
IOVA+9.6%
Iovance Biotherapeutics, Inc.
STOK+3.3%
Stoke Therapeutics, Inc.
LKFT+0.78%
Lakefront Biotherapeutics NV